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Abstract: The histological discrimination of granulomatous cutaneous T-cell lymphomas (CTCLs) from
reactive granulomatous disorders such as sarcoidosis and granuloma annulare (GA) may be difficult due
to overlapping histological features. We analyzed the T-cell receptor gene rearrangement in sarcoidosis
and GA to investigate the value of the detection of clonal T cells as an adjunctive diagnostic marker
in the differentiation between sarcoidosis and GA versus granulomatous CTCLs. Rearrangement of T-
cell receptor ￿ genes was examined by the use of automated high-resolution polymerase chain reaction
fragment analysis in 35 cases of sarcoidosis and 15 cases of GA and compared with a series of 19 cases
of granulomatous CTCLs. A monoclonal T-cell population was found in none of the cases of sarcoidosis
and in 2 of 15 cases of GA (13%). In granulomatous CTCLs, a neoplastic T-cell clone was detected in
94%. Presence of clonal T cells argues in favour of a granulomatous CTCL, while a polyclonal T-cell
population makes the presence of a sarcoidosis or a GA more likely. The analysis of T-cell clonality is a
useful diagnostic adjunct in the differentiation between sarcoidosis and GA from granulomatous CTCLs.
DOI: 10.1097/DAD.0b013e318222f906
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Background: Granulomatous cutaneous T-cell lymphomas (CTCLs) are rare and represent a 73 
diagnostic challenge. Only limited data on the clinicopathological and prognostic features of 74 
granulomatous CTCLs are available. We describe 19 patients with granulomatous CTCLs to 75 
further characterize the clinicopathological, therapeutic and prognostic features.  76 
 77 
Observations: The group included granulomatous mycosis fungoides (GMF; n=15) and 78 
granulomatous slack skin (GSS; n=4) defined according to WHO-EORTC classification for 79 
cutaneous lymphomas. GMF and GSS displayed overlapping histological features and 80 
differed only clinically by the development of bulky skin folds in GSS. Histologically, 81 
epidermotropism of lymphocytes was not a prominent feature and was absent in 9 of 19 82 
(48%) cases. Stable or progressive disease was observed in the most patients despite various 83 
treatment modalities. Extracutaneous spread occurred in 5 of 19 (26%) patients. Second 84 
lymphoid neoplasms developed in 4 of 19 (21%) patients. Six of 19 (32%) patients died due 85 
to their disease. Disease-specific 5-year-survival rate in GMF was 66%.  86 
 87 
Conclusions: GMF and GSS differ clinically, but can histologically not be discriminated. 88 
Development of hanging skin folds is restricted to the intertriginous body regions. 89 
Granulomatous CTCLs show a therapy-resistant slowly progressive course. Nevertheless,The 90 
prognosis in GMF appearsis worse than in classic non-granulomatous MF. 91 
92 
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Introduction 92 
The occurrence of sarcoid-like granulomas is a well known phenomenon in malignant 93 
lymphoma and is most commonly observed in patients with Hodgkin’s disease (HD) 1, 2 . In 94 
contrast, granulomatous features are rarely found in primary cutaneous lymphomas (CL) with 95 
approximately 2% of all CL displaying granulomatous features 3, 4. 96 
Granuloma formation was reported in a broad variety of primary CL 5, 6 such as Sézary 97 
syndrome 7, primary cutaneous anaplastic large T-cell lymphoma 8, subcutaneous panniculitis 98 
like T-cell lymphoma as well as in primary cutaneous B-cell lymphomas (CBCL) 4. 99 
Granulomatous MF is the most common form of granulomatous cutaneous T-cell lymphoma 100 
(CTCLs). In contrast granulomatous slack skin (GSS) is a very rare form of CTCLs and to 101 
date only approximately 50 cases have been reported in the literature 9, 10. In the WHO-102 
EORTC classification for cutaneous lymphomas, GSS is considered as a distinct subtype of 103 
mycosis fungoides (MF) with characteristic clinical and histological features 11, 12.  104 
So far, there are only a limited number of studies on granulomatous CTCLs, particularly 105 
granulomatous MF (GMF). The clinicopathological features and the course of granulomatous 106 
CTCLs are still poorly characterized. The granuloma formation can be very extensive so that 107 
the histologic diagnosis of lymphoma may be delayed and not rarely the findings are initially 108 
misdiagnosed as granulomatous dermatitis 4. There is a controversy whether the presence of 109 
granulomas in CL correlates with a better prognosis 5, 13. Thus, a multicenter study was 110 
conducted to analyze the clinical, histopathological, immunophenotypic and genotypic 111 
features of granulomatous reactions in CTCLs, particularly GMF and GSS, as well as the 112 
course and prognosis of these granulomatous CTCLs. 113 
In this study, we demonstrate that GMF and GSS differ in regard to their clinical presentation, 114 
but show overlapping histological features. This finding has implications on the future 115 
classification of GSS. Our data demonstrate that GMF and GSS exhibit often a slowly 116 
progressive course with only limited response to a broad variety of therapeutic approaches.  117 
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Nevertheless, the prognosis of GMF is worse than in classic, non-granulomatous MF.  118 
 119 
Methods 120 
Patients and biopsies 121 
Twenty-three skin biopsies from 23 well-documented patients from a total of 18 European 122 
Centers were submitted as „granulomatous cutaneous T-cell lymphoma“ by the members of 123 
the EORTC Cutaneous Lymphoma Histopathology Task Force (EORTC CLTF). Cases to be 124 
included and further analyzed had to show prominent granuloma formation or numerous 125 
histiocytic giant cells or a histiocyte-rich infiltrate defined by histiocytes accounting for >25% 126 
of the entire infiltrate. The following clinical data were recorded: sex, age at diagnosis, biopsy 127 
site, clinical manifestation including localization and distribution of skin lesions, TNM stage 128 
at diagnosis according to TNM classification of malignant tumors 14, age at first symptoms (if 129 
available) and age at first biopsy displaying granulomatous features, the results of staging 130 
investigations, treatment, response to treatment and outcome. 131 
Inclusion criteria included H&E and immunohistochemical stainings of diagnostic quality, 132 
written detailed data or photographies of clinical presentation and informations on therapeutic 133 
interventions as well as follow-up on course and outcome.  134 
All biopsy specimens were formalin-fixed and paraffin-embedded. Hematoxylin and eosin 135 
(HE) as well as stainings for elastic fibers were performed. Immunohistochemical stainings 136 
for lymphocytic (CD3, CD4, CD8, CD30) and histiocytic antigens (CD68) were visualized by 137 
Streptavidin-biotin or APAAP method according to standard protocols. Rearrangement of T-138 
cell receptor gamma genes was assessed by PCR as previously described 15, 16.  139 
Statistical analysis was performed using SPSS version 15.0 (SPSS Chicago IL). 140 
 141 
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Results 142 
According to the WHO-EORTC classification for cutaneous lymphomas 11, 12, 19 CTCLs 143 
cases could be identified and classified as GMF (n=15) or granulomatous slack skin (n=4). 144 
Two cases originally submitted as GSS were reclassified as granulomatous MF, since the skin 145 
lesions did not evolve to hanging skin folds during follow-up period. Four additional cases 146 
were classified as primary cutaneous peripheral T-cell lymphoma, unspecified (PTL, NOS) 147 
(n=4) which were excluded from further analysis since the presented study focused on GMF 148 
and GSS. In addition to the 23 CTCLs cases, secondary cutaneous involvement by systemic 149 
T-cell NHL (n=3) including nodal Lennert’s lymphoma (as a variant of nodal peripheral T-150 
cell lymhoma), angioimmunoblastic T-cell lymphoma and one case of nodal CD4+ T-cell 151 
NHL NOS had been submitted, but were excluded from this study due to their primary 152 
extracutaneous origin. 153 
The clinical data, therapy and outcome are presented in Table 1. Table 2 displays the 154 
histopathological, immunophenotypical and genotypic features.  155 
 156 
Group 1: Granulomatous mycosis fungoides (GMF) 157 
Clinical features: This group consisted of 15 patients, 9 males and 6 females resulting in a 158 
male to female ratio of 1.5:1. Median age at diagnosis was 48 years of age with a broad range 159 
(20 to 72 years). In two patients, the disease had started in childhood before age of 10 years. 160 
All patients in this group exhibited patches and plaques (Fig. 1), some of them with atrophy of 161 
the skin, but lack of cutis laxa-like features (Fig. 1). In one patient, the disease was restricted 162 
to a solitary plaque representing unilesional MF. In 5 of 15 (33%) patients, skin lesions were 163 
hyperpigmented (Fig. 2). At the time of diagnosis, 13 of 15 (87%) were in stage I or II 164 
according to TNM staging system 14. First symptoms of the disease had been reported to be 165 
present years or decades (median value: 11 years; range: 1-15 years) before diagnosis of GMF 166 
was established. Four patients had experienced suffered from  other types of lymphoid or 167 
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myeloid neoplasms before or after the occurrence of GMF: Two patients had suffered from 168 
nodal Hodgkin lymphoma (HL), nodular sclerosing type, 20 years before and 4 years after the 169 
occurrence of granulomatous MF. In the third patient nodal CD30-positive anaplastic large-170 
cell lymphoma (ALCL) developed 4 years before the diagnosis of GMF and the fourth patient 171 
had myeloid leukemia in childhood 21 years before the diagnosis of GMF. In all four patients 172 
complete remission (CR) from those second neoplasiasnodal non Hodgkin lymphomas or 173 
myeloid leukemia, respectively, was observed. 174 
Treatment of GMF was heterogeneous involving combined treatment with psoralen-UVA 175 
(PUVA) and interferon-alpha in 7 patients. Three patients received chemotherapy with CHOP 176 
regimen, whereas two patients were treated with monoagent chemotherapy. Radiation was 177 
applied in 7 of 15 patients. Other treatment modalities included topical corticosteroids, 178 
imiquimod, and systemic retinoids. Complete tumor regression was observed in only 3 of 15 179 
(20%) patients, but recurrence occurred within a period of two years in two one patients. In 180 
both patients with complete remission, complete remission followed treatment with 181 
interferon-alpha. Progression of the disease was observed in 6 of 15 (40%) patients and 182 
extracutaneous spread was observed in 5 of 15 (33%) patients with involvement of lymph 183 
nodes, liver and bone marrow (Table 1). In 3 of 15 (20%) patients transformation into CD30+ 184 
large-cell lymphoma phenotype was observed. Six of 15 (40%) patients including the three 185 
patients with transformation into a CD30+ large-cell phenotype died due to lymphoma after a 186 
median follow-up of 5.3 years (median value; range 1-20 yrs) after diagnosis and 16 years 187 
(median value; range 2 to 54 years) after onset of the disease, i.e. the appearance of first 188 
symptoms. Disease-specific 5-year-survival rate in GMF was 66%.  189 
 190 
Histological features: The infiltrate was diffuse (6/15; 40%), nodular (4/15; 27%) (Fig. 3) or 191 
perivascular or periadnexal (5/15; 33%) and extended throughout the entire dermis (8/15; 192 
53%) and into the subcutis in 5 of these cases (33%). Epidermotropism of lymphocytes was a 193 
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prominent feature in only 4 of 15 (27%) and subtle with only a few lymphocytes in another 4 194 
of 15 (27%) cases. In the remaining 7 /15 (47%) biopsies epidermotropism of lymphocytes 195 
could not be detected (Fig. 3). The lymphocytic compartment component of the infiltrate 196 
consisted of small lymphocytes without significant nuclear atypia in 4 of 15 (27%) cases, 197 
whereas small lymphocytes with cerebriform nuclei were found in 5 of 15 (33%). In 6/15 198 
(40%) cases, tumor cells were small to medium-sized with pleomorphic nuclei and in one case 199 
large pleomorphic lymphocytes were intermingled with the predominant small to medium-200 
sized tumor cells. Eosinophils were present and readily identifiable in 9 of 15 (60%) (Fig. 4). 201 
Remarkably, Cclusters of plasma cells, which were not related to overlying ulceration, were 202 
observed in 2 (13%) of the biopsies. Granuloma formation with aggregations of histiocytes 203 
was found in 13 of 15 (87%) cases and multinucleated histiocytic giant cells were present in 8 204 
of 15 (53%) biopsies (Fig. 4 and 5). In all cases with granuloma formation, there was a 205 
sarcoid-like pattern of granulomas (Fig. 4), whereas a granuloma annulare-like pattern could 206 
not be found in any of the biopsies. Granulomas were absent in two biopsies, but numerous 207 
multinucleated giant cells were scattered in a diffuse lymphocytic infiltrate in those two cases 208 
(Fig. 6 and 7). In 4 of 15 (27%) cases, infiltration of dermal or subcutaneous vessels by 209 
lymphocytes was found and in two of these 4 cases numerous multinucleated giant cells were 210 
observed around and within the walls of large veins in the subcutis (Fig. 8). Elastica staining 211 
was available in 12 cases. Loss of elastic fibers throughout the infiltrated areas was found in 212 
all 12 biopsies, but elastophagocytosis was only found in 1 of 12 (8%) biopsies.  213 
 214 
Immunophenotype and Genotype:  215 
The lymphocytes expressed a CD3+ CD4+ CD8- phenoytpe in 12 of 15 (80%) cases. One 216 
case showed expression of TIA-1 by CD4+ lymphocytes. Three of 15 (20%) cases exhibited a 217 
CD3+ CD4- CD8+ cytotoxic phenotype. Clonal rearrangement of TCR gamma genes was 218 
detected by PCR in 13 of 15 (87%) biopsies. 219 
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 220 
Group 2: Granulomatous slack skin (GSS) 221 
Clinical features: The group included 2 males and 2 females. Median age at diagnosis was 46 222 
years (range: 22 to 71 years). All four patients showed poikilodermatous patches and plaques 223 
in the intertriginous areas (axillae, groins) with the development of characteristic bulky skin 224 
folds (Fig. 9). In one patient with additional skin lesions on non-intertriginous areas of the 225 
trunk, only the lesions in the axillae and groins underwent cutis laxa-like changes, whereas 226 
skin lesions at other sites did not evolve in a similar way. All patients experienced an indolent 227 
slowly progressive course without extracutaneous spread and were alive with disease after a 228 
median follow-up of 17 years. One patient developed a second lymphoid neoplasia (CD30+ 229 
lymphoproliferative disorder of the skin) after the occurrence of GSS. Partial remission could 230 
be achieved in two patients by PUVA or topical carmustine. However, none of the other 231 
therapies including surgical excision, topical steroids, nitrogen mustard or systemic therapies 232 
such as IFN-alpha in combination with retinoids were effective and in none of the patients 233 
complete tumor regression was observed. All patients were alive after a median follow-up of 234 
17 years (range 10 to 28 years) resulting in a 5-year-survival rate of 100%. 235 
 236 
Histological features: Five biopsies of the 4 patients were available for histological 237 
evaluation. In 4 of 5 biopsies there was a diffuse lymphocytic infiltrate throughout the entire 238 
dermis and the upper parts of the subcutis were found with numerous scattered multinucleated 239 
giant cells displaying more than 10 nuclei per cell (Fig. 10 and 11). In addition, granuloma 240 
formation was identified in 2 of 4 cases. One biopsy exhibited a lichenoid infiltrate of small to 241 
medium-sized lymphocytes mostly in the upper and mid dermis with sarcoid-like granuloma 242 
and a few giant cells. This pattern was not related to initial disease manifestation, since this 243 
biopsy was performed from established lesions with hanging skin folds. Epidermotropism of 244 
lymphocytes was present in only one case, but absent or very subtle with only a few scattered 245 
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intarepidermal lymphocytes in the remaining three cases. The lymphocytes were small 246 
without nuclear atypia in two cases and small to medium-sized pleomorphic in the remaining 247 
two cases. Eosinophils could be found in all biopsies and mostly scattered plasma cells were 248 
present in 3 of 4 cases. In two cases, infiltration of large veins in the subcutis by 249 
multinucleated giant cells and lymphocytes was observed. Elastica staining revealed loss of 250 
elastic fibers in the infiltrated area in all cases. Elastophagocytosis was subtle and only found 251 
in 2 of 4 cases. 252 
 253 
Immunophenotype and genotype:  254 
In three of four patients, lymphocytes displayed a CD3+ CD4+ CD8- phenotype. In contrast, 255 
one case showed a CD3+ CD4- CD8+ phenotype. Monoclonal rearrangement of TCR gamma 256 
genes could be demonstrated by PCR in all cases. In addition, monoclonal rearrangement of 257 
T-cell receptor beta genes was demostrated by Southern blot technique in one of the cases. 258 
 259 
Comment 260 
In our series GMF was the most common disorder accounting for 79% of the analyzed cases.  261 
Patients affected by GMF and GSS were at diagnosis in their 5th decade with a male 262 
predominance in the GMF. In both disorders, GMF and GSS, the disease extent and 263 
distribution of skin lesions at diagnosis corresponded to TNM stage Ia in the majority of 264 
patients (11 of 19; 58%) with the trunk representing the predilection site (Fig. 1). The clinical 265 
presentation of skin lesions in GMF was not indicative for the histologically detected 266 
granulomatous features (Fig. 1). GMF manifested with hyperpigmented skin lesions in a third 267 
of the patients (Fig. 2). Hyperpigmented MF had been reported as a common feature in CD8+ 268 
MF 17, but none of the cases with hyperpigmented skin lesions in our series displayed a CD8+ 269 
cytotoxic T-cell phenotype.  270 
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PUVA and/or IFN-alpha as well as radiotherapy were the most commonly employed 271 
treatment modalities. Complete tumor regression could be achieved in only 3 of 15 (20%) 272 
patients with GMF. In half of the patients, the disease showed a slowly progressive course.  273 
Extracutaneous spread was observed in a third of GMF patients and was associated with 274 
transformation into CD30+ anaplastic large-cell lymphoma (ALCL) in 20% of the patients. . 275 
Six of 15 (40%) patients with GMF including the three patients with large-cell transformation 276 
died due to the disease.  The percentage of patients with unfavourable outcome is identical to 277 
the study by Chen et al. who reported death due to the disease in 40% of GMF patients 13. 278 
Whereas the occurence of granulomas in MF has been considered to be associated with a 279 
favorable prognosis by some authors 6, 18, other investigators could not confirm this 280 
observation 19-21. These findings demonstrate that GMF is not associated with a better 281 
prognosis compared to classic, non-granulomatous MF. In fact, 5-year-survival of GMF 282 
(66%; Figure 12) is worse than in classic MF and similar to folliculotropic MF 22, 23. 283 
In contrast, all patients with GSS were still alive after a median follow-up of 17 years despite 284 
GSS was therapy-resistant and CR could not be achieved in any of the patients. Recently, 285 
response of GSS to topical nitrogen mustard was observed in two patients 24, but definitive 286 
therapy of GSS has yet to be established. Extracutaneous spread is exceedingly rare in GSS 287 
and did not occur in our series of GSS patients. 288 
Patients suffering from GMF and GSS are known to be at risk for the development of second 289 
lymphoid neoplasias. In our series, 4 of 19 (21%) patients with GMF or GSS had experienced 290 
a second lymphoma before or after occurrence of granulomatous CTCLs and an additional 291 
patient had had myeloid leukemia. This prevalence is lower than reported in the literature with 292 
48% of the GSS patients with second lymphoid neoplasia. 10, 25, 26. These patients may be 293 
overrepresented in the literature due to the development of a second lymphoma and eventually 294 
misinterpretation of large-cell transformation as development of a second ALCL unrelated to 295 
GSS. Hodgkin lymphoma is the most common second neoplasia in patients with 296 
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granulomatous CTCLs in the literature as well as in our series 10, 25, 26. The time interval 297 
between lymphoid neoplasias and GMF or GSS may be years or even decades as seen in one 298 
patient of our series who developed nodal Hodgkin lymphoma 20 years before onset of GMF. 299 
Thus, life-long observation of patients with GMF and GSS is required. 300 
Histologically, a diffuse infiltrate of lymphocytes extending throughout the entire dermis and 301 
the subcutis was the most common growth pattern (Fig. 4). Granulomas were sarcoid-like in 302 
all biopsies (Fig. 6). Other patterns of granulomatous reactions such as granuloma annulare-303 
like, palisaded or necrobiotic granuloma as reported in the literature 27-30 were not found in 304 
our series. In 70% of the CTCLs cases, the infiltrates contained histiocytic giant cells 305 
displaying 10 or more nuclei (Fig. 11). Remarkably, infiltration of the vessel walls of large 306 
veins by small lymphocytes and even by large multinucleated histiocytic giant cells was 307 
observed in a third of the cases (Fig. 8). This is far more common than reported in the 308 
literature 4, 5. The lymphocytic compartment in GMF and GSS was composed of small 309 
lymphocytes, which showed nuclear atypia in half of the cases (Fig. 6). Medium-sized 310 
pleomorphic lymphocytes were admixed in almost half of GMF and GSS cases (Fig. 5). 311 
Epidermotropism of lymphocytes was previously reported as a common finding in 312 
granulomatous CTCLs and considered to be a useful histological feature for discrimination of 313 
granulomatous CTCLs from reactive granulomatous disorders 5. In our series, however, 314 
epidermotropism was absent in almost half of the cases limiting its value as a diagnostic 315 
marker in GMF and GSS. Although classic MF commonly displays epidermotropism, this 316 
histological feature is not a prerequisite for MF according to WHO-EORTC classification. 317 
Thus, lack of epidermotropism does not exclude the diagnosis of MF. In those cases, 318 
diagnosis of MF relies on the characteristic clinical presentation with patches and plaques.  319 
Diagnosis in granulomatous CTCLs is often delayed with a latency of years to decades after 320 
onset of first symptoms. Diagnosis is particularly challenging in cases with predominant 321 
granuloma formation in the absence of nuclear atypia or epidermotropism of tumor cells. 322 
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Detection of a neoplastic T-cell clone, which was present in nearly all cases may thus be a 323 
useful diagnostic adjunct in granulomatous CTCLs.  324 
The histological features of GSS have been reported as pathognomonic with a diffuse 325 
lymphocytic infiltrate harbouring numerous scattered multinucleated giant cells 5, 31 (Fig. 6 326 
and 7), but identical histological features can also be observed in GMF 32. Remarkably, this 327 
pattern was in our series also found in two of the 15 GMF cases in our series (Fig. 6-7) and is 328 
therefore not pathognomonic for GSS. These observations demonstrate that GMF and GSS 329 
differ clinically but show overlapping histological findings and therefore can not be 330 
discriminated by histology alone. In fact,It should be recalled that both diseases represent 331 
merelyare considered variants of a single disease 33. It implies that GSS may be listed in 332 
future classifications for cutaneous lymphomas as another variant and not a subtype of MF. 333 
As emphasized by Scarabello and coworkers, diagnosis of GSS should rest on clinical 334 
grounds and be restricted to those patients presenting clinically with characteristic bulky skin 335 
lesions 4.  336 
The classic pathogenetic concept links the development of hanging skin folds in GSS to 337 
destruction of elastic fibers due to elastophagocytosis by histiocytic giant cells. However, loss 338 
of elastic fibers was found in all examined cases. The extent of loss of elastic fibers correlated 339 
with the extent of the granulomatous infiltrate, but was not restricted to GSS. Moreover, only 340 
skin lesions in skin folds such as the axillae and the groins underwent cutis laxa-like changes, 341 
whereas skin lesions present at other body sites did not evolve in a similar way. These 342 
observations suggest that development of hanging skin folds is merely a location-related 343 
phenomenon and not solely thea result of the destruction of elastic fibers. Hypothetically, the 344 
continuous stretching of elastic fibers in the intertriginous body areas during physiological 345 
movements may facilitate the loss of their function when these regions become affected by 346 
lymphomatous infiltrates.  347 
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The pathogenetic mechanisms of granuloma formation in lymphoid neoplasms is poorly 348 
understood. Granulomatous reaction has been regarded by some authors as a local tissue 349 
response to the infiltrating malignant cells or their antigens 34, but this hypothesis has been 350 
criticized by others based on the occurrence of granulomas in histologically lymphoma-free 351 
tissues 35. In addition, treatment with IFN alpha or bexarotene 36 may induce sarcoid-like 352 
reactions. However, granuloma formation in our series was not related to previous therapy.  353 
In sarcoidosis, granuloma formation is preceded by a hyperactive T-helper 1 biased CD4+ T-354 
cell response 37. Recent data indicate that the absence or deficiency of CD1d-restricted natural 355 
killer T-cells could contribute to the persistent T-cell activity leading to granuloma formation 356 
38. On the other hand, granuloma formation was also found in GMF with tumor cells 357 
expressing both Th1 and Th2 chemokine receptors 39. To our knowledge, the presence and 358 
functional status of this subset of T-cells has not been investigated in granulomatous forms of 359 
CL. Recently, genetic alterations with t(3;9)(q12;p24) have been reported in a case of GSS 37 360 
which may indicate genetic predisposition to granuloma formation. The pathogenetic 361 
processes underlying granuloma formation in granulomatous CTCLs remain to be elucidated. 362 
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Tables 466 
Table 1:  467 
Clinical and therapeutic data of a series of 19 patients with granulomatous cutaneous T-cell 468 
lymphomas. 469 
Legend: 470 
ALCL: anaplastic large cell lymphoma; ACR: alive with complete remission; AWD: alive 471 
with disease; BM-TPL: bone marrow transplantation, Chth: chemotherapy; CR: complete 472 
tumor regression; CS: topical corticosteroids; Distrib: Number of skin lesions; DOD: death 473 
due to disease; Extr: extremities; GMF: granulomatous mycosis fungoides; GSS: 474 
granulomatous slack skin; HL: Hodgkin lymphoma; HN2: nitrogen mustard; IFN: interferon-475 
alpha; Imiq: imiquimod; LPD: lymphoproliferative disorders;LN: lymph nodes; MC: 476 
mechlorethamine; Mult: multiple; Nod: nodule(s); Pat: patches; Phago: phagocytosis; Pigm: 477 
hyperpigmented; Plaq: plaques; PD: progressive disease; PR: partial tumor regression; Predn: 478 
Prednison p.o; PUVA: psoralen-Ultraviolett A light therapy; Resp: response to treatment; Ret: 479 
retinoids; RT: Radiation therapy; SD: stable disease; S: small; S-M: small to medium-sized; 480 
Sol: solitary 481 
 482 
Table 2: 483 
Histological, immunophenotypic and genotypic data of a series of 19 patients with 484 
granulomatous cutaneous T-cell lymphomas. 485 
Legend: 486 
Angio: angiocentric growth; El: Elastica-staining; Eos: eosinophilic granulocytes; M: 487 
medium-sized; Perivasc: perivascular; Pleo: pleomorphic; TCR: T-cell receptor 488 
rearrangement (+: monoclonal, -: polyclonal). 489 
490 
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Figures 490 
Fig. 1: Granulomatous mycosis fungoides: Erythematous patches and plaques. Note: Clinical 491 
features are not suggestive for granulomatous histology. 492 
 (left side) and atrophic skin lesions without bulky skin folds (right side). 493 
 494 
Fig. 2: Granulomatous mycosis fungoides: Hyperpigmented patches in granulomatous MF. 495 
 496 
Fig. 3: Granulomatous mycosis fungoides: Dense nodular lymphocytic infiltrates throughout 497 
the entire dermis. Note the grenz zone and the absence of epidermotropism. H&E, scanning 498 
magnification. 499 
 500 
Fig. 4: Granulomatous mycosis fungoides: Infiltrate of small lymphocytes with granuloma 501 
formation (H&E, original magnification 40X) (left side). The lymphocytes exhibitti nuclear 502 
atypia. Note admixed eosinophils (H&E, original magnification 200X) (right side). 503 
 504 
Fig. 5: Granulomatous mycosis fungoides: Infiltrate with histiocytic multinucleated giant 505 
cells. H&E, original magnification 100X. 506 
 507 
Fig. 6: Granulomatous mycosis fungoides: Diffuse lymphocytic infiltrate covering all  dermal 508 
layers. H&E, scanning magnification. 509 
 510 
Fig. 7: Granulomatous mycosis fungoides: Scattered multinucleated giant cells. Absence of 511 
granuloma formation (H&E, original magnification 20X). Note scattered multinucleated giant 512 
cells with phagocytosis of small lymphocytes (H&E, original magnification 100X) (inlay) 513 
 514 
 515 
  22 
Fig. 8: Infiltration of large subcutaneous vein by the infiltrate containing multinucleated giant 516 
cells. H&E, original magnification 20X. 517 
 518 
Fig. 9: Granulomatous slack skin: Bulky skin folds in the right axilla. 519 
 520 
Fig. 10: Granulomatous slack skin: Dense lymphocytic infiltrate throughout the entire dermis. 521 
H&E, scanning magnification. 522 
 523 
Fig. 11: Granulomatous slack skin: Numerous multinucleated giant cells, but lack of 524 
granuloma formation. H&E, original magnification 100X. 525 
 526 
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Case Sex Age Diagnosis Localization Lesion type Distrib Stage TNM Therapy Resp Extracutaneous 2nd neoplasia Outcome 
Follow-
up 
  (years) Gran MF        spread   (years) 
1 F 51 GMF Buttocks, Extr Pap-Pat mult I b T2N0M0 IFN, PUVA PR   AWD 8 
2 F 20 GMF Face, Arm Pat mult III T4N0M0  IFN, Chth SD LN, spleen, ocular; DOD 1 
3 M 35 GMF Groin Plaq sol I a T1N0M0 CS, MC, RT; IFN CR   ACR 20 
4 F 81 GMF Generalized Plaq (pigm) mult I b T2N0M0 CS, MC PR   AWD 6 
5 M 39 GMF Generalized Plaq Nod (pigm) mult II b T3N0M0 RT, Chth  PR  HL DOD 2 
6 M 52 GMF Generalized Pat-Plaq-Nod mult I b T2N0M0 PUVA, RT PD 
BM, retroperitoneal LN, 
spleen  DOD 1 
7 F 64 GMF Trunk Pat mult I a T1N0M0 Imiq, IFN, PUVA, RT CR LN  ACR 6 
8 F 61 GMF Generalized Pat-Plaq (pigm) mult I a T1N0M0 Chth SD   AWD 1 
9 M 57 GMF Generalized Pat-Plaq mult IV a T3N2M0 Chth CR LN  AWD 4 
10 M 47 GMF Trunk, legs Plaq mult II a T1N1M0 Predn PD  HL AWD 5 
11 M 30 GMF Trunk 
Plaq 
(poikilodermatous) mult I a T1N0M0 PUVA, IFN PR   AWD 4 
12 F 28 GMF Trunk Pat-Plaq mult I a T1N0M0 PUVA, RT, IFN PD LN, BM, liver Myeloid leukemia DOD 9 
13 M 27 GMF Trunk Plaq- Nod mult I a T1N0M0 CS, PUVA, IFN, Ret SD   AWD 7 
14 M 72 GMF Generalized Plaq-Nod mult I b T2N0M0 PUVA, IFN, RT, Chth PD   DOD 1 
15 M 47 GMF Legs Plaq-Nod (pigm) mult I a T1N0M0 CS, IFN, Ret, RT PD  
Nodal CD30+ 
ALCL DOD 5 
               
   GSS            
16 M  55 GSS Groin Pat-Plaq - hang mult I a T1N0M0 PUVA, Ret, IFN PR  
Cutan CD30+ 
LPD AWD 10 
17 M 71 GSS Axilla, groins Plaq- hang mult I a T1N0M0 n.a. n.a.   AWD 16 
18 F 35 GSS Trunk, groin, leg Pat-Plaq -hang mult I a T1N0M0 
Excision, CS, HN2, 
PUVA, IFN PD   AWD 15 
19 F 22 GSS 
Trunk 
incl.axilla/groins Pat-Plaq -hang mult I a T1N0M0 Excision, Carmustine PR   AWD 28 
               
 
Case Diagnosis Growth Pattern 
Epidermo- 
tropism Cell size Granuloma
Giant 
cells El loss 
Elasto-
phago Eos Plasm Angio Phenotype Genotype 
 Gran MF             
1 GMF diffuse  + S-M pleo  +  ++  ++  +  +  -   + CD3+ 4- 8+ 30- TIA1+ TCR+ 





up S  +  + (few) n.a. n.a.  -   -   -  CD3+ 4+ TCR+ 
4 GMF perivasc  -  S  -   + (few) n.a. n.a.  -   -   -  n.a. TCR+ 
5 GMF perivasc/periadn  + S-M pleo  + (few)  +  +  -   +  -   -  




folliculotropic perifoll/periadn  + S  +   +  +  -   +  -   -  CD3+ 4+ 8- 30- TIA1- TCR+ 
7 GMF perivasc -nod  -  
S-M -(L) 
pleo  +   -  +  -  
 + 
(few)  +  -  CD3+ 4-- 8+ 30- TIA1+/- TCR+ 
8 GMF  nodular  -  S-M pleo  +   -   ++  -   -   -   -  CD3+ 4+ 30- TIA1+ TCR+ 
9 GMF nodular  -/+ S  +   -   +  -   ++  -   -  CD3+ 4+ 8- 30- TIA1- TCR+ 
10 GMF nodular  -  S  +  -   +  -  +  -   -  CD3+ CD8+ TCR- 
11 GMF diffuse  -  S   -   ++  +++  -  -   -   + CD3+ 4+ 8- 30- TIA1- TCR+  
12 GMF  diffuse  + S-M pleo  +  -  +  -  +  -   + CD3+ 4+ 8- 30- TIA1- TCR+  
13 GMF diffuse   -/+ S  +  -   +  -  +  -   + CD3+ 4+ 8- 30- TIA1- TCR+  
14 GMF nodular  -/+ S  +  -   ++  -  +  +  -  CD3+ 4+ 8- 30- TIA1- TCR+  
15 GMF diffuse  -  S  +  +  +++  -   -   -   -  CD3+ 4+ 8- 30- TIA1- TCR+  
              
 GSS             
16 GSS diffuse  -  S  -  +  ++  -  
 + 
(few)  +  + CD3+ 4+ 8- 30- TIA1- TCR+ 
17 GSS diffuse  - S  +  ++  +  + 
 + 
(few)  +  -  
CD3+ 4- 8+ 30- TIA1- 
Granzyme B- TCR+ 
18 GSS diffuse  -  S-M pleo  -   ++  +  +  +  -   -  CD3+ 4+ 8- TCR+ 
19 GSS diffuse  + S-M pleo  -  ++  ++  -   +   + CD3+ 4+ 5- 8-  TCR+ 
 
